Stenotrophomonas maltophilia: Biology, Drug Resistance, and Molecular Detection

Stenotrophomonas maltophilia belongs to the family Xanthomonadaceae and is a Gram-negative, rod-shaped bacterium. It is strictly aerobic and requires oxygen for growth. The organism grows well on common laboratory media including nutrient agar, blood agar, and MacConkey agar, where it forms non-lactose-fermenting colonies that appear colorless or pale pink.

Colonies are typically smooth, moist, and well-defined, with a diameter of approximately 1–2 mm. After extended incubation, some strains produce a characteristic pale yellow pigment. The optimal growth temperature ranges from 30–37°C, with an optimum around 35°C, and the bacterium does not grow at 4°C, which helps differentiate it from certain Pseudomonas species. Growth occurs best in neutral to slightly alkaline conditions (pH 6.0–8.0).

Biochemically, the organism is oxidase-negative, which distinguishes it from Pseudomonas aeruginosa. It is positive for lysine decarboxylase and DNase activity and is capable of oxidizing maltose and glucose (producing acid without gas), but it does not ferment lactose. Its strong maltose utilization is reflected in its species name.

Stenotrophomonas maltophilia is widely found in environmental reservoirs such as soil, water, and plant rhizospheres. It can also colonize human respiratory and gastrointestinal tracts without causing disease.

In healthcare settings, the bacterium can persist on moist surfaces and medical devices, including catheters and ventilator systems. Its ability to form biofilms enhances survival and facilitates transmission in hospital environments. Infection typically occurs in susceptible hosts rather than through high intrinsic virulence.

Stenotrophomonas maltophilia is a well-recognized cause of nosocomial infections. It is most commonly associated with respiratory tract infections such as pneumonia and bronchitis, particularly in mechanically ventilated patients.

The bacterium can also cause bloodstream infections, especially catheter-related bacteremia, as well as infective endocarditis. Other infections include wound infections, burn-related infections, and urinary tract infections associated with indwelling catheters.

Although infections in animals have been reported, including respiratory or gastrointestinal infections in livestock and poultry, its primary clinical significance lies in human disease. Mortality rates in severe infections, particularly bacteremia and pneumonia, can be high.

Laboratory diagnosis begins with microscopic examination, where the bacterium appears as slender Gram-negative rods measuring approximately 0.5 × 1.5 μm, arranged singly, in pairs, or short chains. Culture-based identification reveals gray-white colonies on blood agar, typically without hemolysis or occasionally with weak alpha hemolysis.

Biochemical identification relies on key reactions including oxidase-negative, lysine decarboxylase-positive, and DNase-positive profiles, along with the ability to oxidize maltose and mannitol but not lactose.

Molecular methods provide more accurate and rapid identification. Sequencing of the 16S rRNA gene enables species-level identification, while detection of specific genetic targets such as Sm23S rRNA or gyrB genes further improves specificity. Probe-based real-time PCR assays offer sensitive and rapid detection for clinical and research applications.

Stenotrophomonas maltophilia is known for its intrinsic multidrug resistance. It exhibits natural resistance to many antibiotic classes, including β-lactams (especially carbapenems), aminoglycosides, and macrolides.

The preferred first-line treatment is trimethoprim-sulfamethoxazole. Alternative options, guided by antimicrobial susceptibility testing, may include minocycline, tigecycline, levofloxacin (in susceptible strains), and certain combination therapies for severe infections.

Resistance mechanisms include overexpression of efflux pump systems that actively expel antibiotics, production of metallo-β-lactamases that hydrolyze β-lactam antibiotics, and biofilm formation that reduces antibiotic penetration and protects bacteria from host immune responses.

Effective management requires a combination of targeted antimicrobial therapy, removal or replacement of contaminated medical devices, and strict infection control practices to prevent transmission in healthcare environments.